GASTAUD , Lauris

Last name: GASTAUD

First name: Lauris

2013 (v1)

Journal article

Metadata-only

Major Efficacy of Trabectedin in 2 Metastatic Osteosarcoma Patients with Wild-Type Asp1104 ERCC5 Tumor Status

Gastaud, Lauris Saada-Bouzid, Esma Morvan, Valérie Le

International audience

Uploaded on: December 4, 2022
2019 (v1)

Journal article

Metadata-only

Oncologic and visual outcomes after postoperative proton therapy of localized conjunctival melanomas

Thariat, Juliette Salleron, Julia Maschi, Celia

Introductionconjunctival melanomas have high local relapse rates. Oncologic and visual outcomes can be improved with proton therapy and no-touch surgery.Material and methodsa monocentric retrospective study of consecutive patients treated with surgery and proton therapy for conjunctival melanoma was conducted. Proton therapy was performed to a...

Uploaded on: December 4, 2022
February 9, 2021 (v1)

Journal article

Metadata-only

Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia

Pautas, Cécile Raffoux, Emmanuel Lambert, Juliette

The phase 3 ALFA-0701 trial demonstrated improved outcomes with fractionated-dose gemtuzumab ozogamicin (GO) combined with standard chemotherapy vs. standard chemotherapy alone in adults with de novo acute myeloid leukemia (AML). We examined post-transplant outcomes and occurrence of hepatic veno-occlusive disease/sinusoidal obstruction...

Uploaded on: December 4, 2022
2023 (v1)

Journal article

Metadata-only

Single-Masked Randomized Phase 2 Study Assessing 2 Forms of Hypofractionated Proton Therapy in Patients With Large Choroidal Melanomas

Thariat, Juliette Mathis, Thibaud Pace-Loscos, Tanguy

No description

Uploaded on: November 25, 2023
June 11, 2013 (v1)

Journal article

Metadata-only

Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.

Cluzeau, Thomas Mounier, Nicolas Karsenti, Jean-Michel

IPSS-R classifies cytogenetic abnormalities into five prognostic groups for survival. Monosomal karyotype (MK) is not a subgroup of IPSS-R. Additional prognostic information from MK in poor and very poor karyotype has been recently shown. The aim of our study was to determine the prognostic value of IPSS-R and MK for response and survival in...

Uploaded on: December 4, 2022
November 30, 2015 (v1)

Journal article

Metadata-only

Central nervous system involvement by malignant cells is a rare complication of Waldenström macroglobulinemia, and this clinicopathological entity is referred to as the Bing-Neel syndrome. There is currently no consensus on the diagnostic criteria, therapeutic approaches and response evaluation for this syndrome. In this series, we retrospectively analyzed 44 French patients with Bing-Neel syndrome. Bing-Neel syndrome was the first manifestation of Waldenström macroglobulinemia in 36% of patients. When Waldenström macroglobulinemia was diagnosed prior to Bing-Neel syndrome, the median time interval between this diagnosis and the onset of Bing-Neel syndrome was 8.9 years. This study highlights the possibility of the occurrence of Bing-Neel syndrome without any other evidence of progression of Waldenström macroglobulinemia. The clinical presentation was heterogeneous without any specific signs or symptoms. Biologically, the median lymphocyte count in the cerebrospinal fluid was 31/mm(3). Magnetic resonance imaging revealed abnormalities in 78% of the cases. The overall response rate after first-line treatment was 70%, and the overall survival rate after the diagnosis of Bing-Neel syndrome was 71% at 5 years. Altogether, these results suggest that Bing-Neel syndrome should be considered in the context of any unexplained neurological symptoms associated with Waldenström macroglobulinemia. The diagnostic approach should be based on cerebrospinal fluid analysis and magnetic resonance imaging of the brain and spinal axis. It still remains difficult to establish treatment recommendations or prognostic factors in the absence of large-scale, prospective, observational studies.

Simon, Laure Fitsiori, Aikaterini Lemal, Richard

Central nervous system involvement by malignant cells is a rare complication of Waldenström macroglobulinemia, and this clinicopathological entity is referred to as the Bing-Neel syndrome. There is currently no consensus on the diagnostic criteria, therapeutic approaches and response evaluation for this syndrome. In this series, we...

Uploaded on: December 4, 2022
2018 (v1)

Journal article

Metadata-only

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

Itzykson, Raphael Fournier, Elise Braun, Thorsten

60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, DEC 01-04, 2018

Uploaded on: December 3, 2022
2020 (v1)

Journal article

Metadata-only

Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

Gardin, Claude Pautas, Cécile Fournier, Elise

In this study, we aimed to refine prognostication of older with acute myeloid leukemia (AML) after intensive chemotherapy. Five hundred and nine patients aged 60 years or older (median age, 68 years) were prospectively enrolled in the intensive Acute Leukemia French Association (ALFA)-1200 trial between 2012 and 2016, and 471 patient samples...

Uploaded on: December 4, 2022
2021 (v1)

Journal article

Metadata-only

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Itzykson, Raphael Fournier, Elise Berthon, Celine

To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) >= 60 years of age treated with 7+3, we sequenced 37 genes in 471patients fromtheALFA1200 (Acute Leukemia FrenchAssociation) study (median age, 68 years). Mutation patterns and OS differed between the 84 patients...

Uploaded on: December 3, 2022
November 15, 2022 (v1)

Journal article

Metadata-only

Therapy Related Myeloid Neoplasms Following PARP Inhibitors : Real-Life Experience

Marmouset, Vincent Decroocq, Justine Garciaz, Sylvain

No description

Uploaded on: March 25, 2023

GASTAUD , Lauris

Recent uploads